Healthcare
Live Price
Offline$13.75
-2.27% today
1Y Change
-32.56%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Summit Therapeutics Inc. (SMMT) is a Healthcare stock with a market cap of $12.50B and listed on NASDAQ. The stock last traded around $13.75 and down 32.6% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -364.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -364.5%, free cash flow -127.5% with operating margin 0.0% and ROIC -215.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SMMT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SMMT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SMMT Max Drawdown
-55.49%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SMMT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.8M
+156.9% YoY
FY Net Income
-$88.6M
-12.5% YoY
Free Cash Flow
-$72.9M
-72.7% YoY
Revenue Growth
+0.0%
EPS Growth
-364.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 704K | 2M |
| Gross Profit | -108K | -15M | -2M | -2M | 2M |
| Operating Income | -1.1B | -211M | -90M | -79M | -86M |
| EBITDA | -801M | -213M | -69M | -73M | -86M |
| Net Income | -1.1B | -221M | -615M | -79M | -89M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 225M | 105M | 71M | 349M | 72M |
| Total Assets | 751M | 436M | 203M | 664M | 113M |
| Total Liabilities | 92M | 47M | 125M | 538M | 30M |
| Shareholder Equity | 659M | 389M | 78M | 127M | 83M |
| Total Debt | 21M | 7M | 106M | 519M | 3M |
| Net Debt | -204M | -98M | 35M | 170M | -69M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
73M
-74.6% YoY
Capital Expenditures
306K
+51.0% YoY
Free Cash Flow
73M
-72.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-291.2%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.